Recombinant Technologies
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- Chairmans and MDs address to shareholders
- Announcement of buy-back
- Appointment of Paul Perreault as Executive Director
- New US$500 million Private Placement
- Full Year Results, Appendix 4E and Analysts Presentation
Later from CSL
- Chairman`s Address to Shareholders
- CSL to acquire Novartis influenza vaccine business
- IDELVION(R) (rFIX-FP) - European Commission Approval
- Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval
- AFSTYLA (rFVIII-Single Chain) FDA approval
Follow CSL into a list and get an email when it puts out news.
Follow CSL